# Daniela Galimberti

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 297 papers | 21,120 citations | 62 h-index | 139 g-index |
| 305 ext. papers | 24,643 ext. citations | 6.1 avg, IF | 5.81 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 297 | Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nature Genetics*, **2013**, 45, 1452-8 | 36.3 | 2714 |
| 296 | Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. *Nature*, **2011**, 476, 214-9 | 50.4 | 1948 |
| 295 | Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. *Nature Genetics*, **2009**, 41, 1094-9 | 36.3 | 1819 |
| 294 | Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nature Genetics*, **2011**, 43, 429-35 | 36.3 | 1421 |
| 293 | Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. *Nature Genetics*, **2013**, 45, 1353-60 | 36.3 | 934 |
| 292 | Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. *Nature Genetics*, **2017**, 49, 1373-1384 | 36.3 | 508 |
| 291 | APOE and Alzheimer disease: a major gene with semi-dominant inheritance. *Molecular Psychiatry*, **2011**, 16, 903-7 | 15.1 | 391 |
| 290 | Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. *Lancet Neurology, The*, **2015**, 14, 253-62 | 24.1 | 328 |
| 289 | The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. *Alzheimerjs and Dementia*, **2011**, 7, 386-395.e6 | 1.2 | 291 |
| 288 | A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. *Cell*, **2008**, 133, 1149-61 | 56.2 | 263 |
| 287 | SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Neurology*, **2012**, 79, 1556-62 | 6.5 | 228 |
| 286 | Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. *Archives of Neurology*, **2006**, 63, 538-43 | | 222 |
| 285 | Frontotemporal dementia and its subtypes: a genome-wide association study. *Lancet Neurology, The*, **2014**, 13, 686-99 | 24.1 | 207 |
| 284 | Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. *Acta Neuropathologica*, **2016**, 131, 925-33 | 14.3 | 201 |
| 283 | The cornea in Sjogren's syndrome: an in vivo confocal study. *Investigative Ophthalmology and Visual Science*, **2007**, 48, 2017-22 | | 186 |
| 282 | Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. *Multiple Sclerosis Journal*, **2015**, 21, 1013-24 | 5 | 181 |
| 281 | Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. *Brain*, **2008**, 131, 3081-91 | 11.2 | 180 |

| | | | |
|---|---|---|---|
| 280 | DNA methylation in repetitive elements and Alzheimer disease. *Brain, Behavior, and Immunity*, **2011**, 25, 1078-83 | 16.6 | 157 |
| 279 | Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. *Neurobiology of Aging*, **2006**, 27, 1763-8 | 5.6 | 153 |
| 278 | Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. *Neurobiology of Aging*, **2006**, 27, 262-9 | 5.6 | 152 |
| 277 | Convergent genetic and expression data implicate immunity in Alzheimer's disease. *Alzheimerjs and Dementia*, **2015**, 11, 658-71 | 1.2 | 146 |
| 276 | Selective DNA methylation of BDNF promoter in bipolar disorder: differences among patients with BDI and BDII. *Neuropsychopharmacology*, **2012**, 37, 1647-55 | 8.7 | 145 |
| 275 | Circulating miRNAs as potential biomarkers in Alzheimer's disease. *Journal of Alzheimerjs Disease*, **2014**, 42, 1261-7 | 4.3 | 143 |
| 274 | Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis. *Neuroscience Letters*, **2011**, 504, 9-12 | 3.3 | 138 |
| 273 | TREM2 regulates microglial cell activation in response to demyelination in vivo. *Acta Neuropathologica*, **2015**, 129, 429-47 | 14.3 | 136 |
| 272 | Consensus guidelines for lumbar puncture in patients with neurological diseases. *Alzheimerjs and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2017**, 8, 111-126 | 5.2 | 128 |
| 271 | Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. *Nature Communications*, **2018**, 9, 4273 | 17.4 | 125 |
| 270 | Corneal involvement in rheumatoid arthritis: an in vivo confocal study. *Investigative Ophthalmology and Visual Science*, **2008**, 49, 560-4 | | 110 |
| 269 | Heterozygous TREM2 mutations in frontotemporal dementia. *Neurobiology of Aging*, **2014**, 35, 934.e7-10 | 5.6 | 107 |
| 268 | Vascular endothelial growth factor gene variability is associated with increased risk for AD. *Annals of Neurology*, **2005**, 57, 373-80 | 9.4 | 107 |
| 267 | Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study. *Neurobiology of Aging*, **2018**, 62, 191-196 | 5.6 | 104 |
| 266 | Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. *Brain*, **2015**, 138, 918-31 | 11.2 | 103 |
| 265 | The C9orf72 repeat expansion itself is methylated in ALS and FTLD patients. *Acta Neuropathologica*, **2015**, 129, 715-27 | 14.3 | 101 |
| 264 | Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients. *Annals of Neurology*, **2003**, 53, 547-8 | 9.4 | 101 |
| 263 | Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. *Multiple Sclerosis Journal*, **2013**, 19, 1802-9 | 5 | 99 |

| | | | |
|---|---|---|---|
| 262 | Autosomal dominant frontotemporal lobar degeneration due to the C9ORF72 hexanucleotide repeat expansion: late-onset psychotic clinical presentation. *Biological Psychiatry*, **2013**, 74, 384-91 | 7.9 | 94 |
| 261 | Disease-modifying treatments for Alzheimer's disease. *Therapeutic Advances in Neurological Disorders*, **2011**, 4, 203-16 | 6.6 | 91 |
| 260 | Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease. *PLoS ONE*, **2014**, 9, e94661 | 3.7 | 90 |
| 259 | Production of monocyte chemoattractant protein-1 in amyotrophic lateral sclerosis. *Muscle and Nerve*, **2005**, 32, 541-4 | 3.4 | 88 |
| 258 | Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. *Molecular Neurodegeneration*, **2015**, 10, 64 | 19 | 87 |
| 257 | Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. *Neurobiology of Aging*, **2006**, 27, 904-5 | 5.6 | 85 |
| 256 | Investigation of c9orf72 in 4 neurodegenerative disorders. *Archives of Neurology*, **2012**, 69, 1583-90 | | 83 |
| 255 | EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease. *European Journal of Neurology*, **2015**, 22, 889-98 | 6 | 81 |
| 254 | Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis. *Multiple Sclerosis Journal*, **2013**, 19, 1938-42 | 5 | 81 |
| 253 | Alpha-MSH peptides inhibit production of nitric oxide and tumor necrosis factor-alpha by microglial cells activated with beta-amyloid and interferon gamma. *Biochemical and Biophysical Research Communications*, **1999**, 263, 251-6 | 3.4 | 80 |
| 252 | MicroRNA and mRNA expression profile screening in multiple sclerosis patients to unravel novel pathogenic steps and identify potential biomarkers. *Neuroscience Letters*, **2012**, 508, 4-8 | 3.3 | 79 |
| 251 | Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease. *Molecular Psychiatry*, **2013**, 18, 461-70 | 15.1 | 77 |
| 250 | Optimal plasma progranulin cutoff value for predicting null progranulin mutations in neurodegenerative diseases: a multicenter Italian study. *Neurodegenerative Diseases*, **2012**, 9, 121-7 | 2.3 | 77 |
| 249 | Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 8050-4 | 11.5 | 74 |
| 248 | Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populations. *Neurobiology of Aging*, **2011**, 32, 756.e11-5 | 5.6 | 72 |
| 247 | Progranulin plasma levels as potential biomarker for the identification of GRN deletion carriers. A case with atypical onset as clinical amnestic Mild Cognitive Impairment converted to Alzheimer's disease. *Journal of the Neurological Sciences*, **2009**, 287, 291-3 | 3.2 | 72 |
| 246 | Epigenetic modulation of BDNF gene: differences in DNA methylation between unipolar and bipolar patients. *Journal of Affective Disorders*, **2014**, 166, 330-3 | 6.6 | 71 |
| 245 | Progress in Alzheimer's disease. *Journal of Neurology*, **2012**, 259, 201-11 | 5.5 | 71 |

| | | | |
|---|---|---|---|
| 244 | MCP-1 in Alzheimer's disease patients: A-2518G polymorphism and serum levels. *Neurobiology of Aging*, **2004**, 25, 1169-73 | 5.6 | 70 |
| 243 | Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. *Multiple Sclerosis Journal*, **2011**, 17, 819-29 | 5 | 69 |
| 242 | Hypermethylation of the CpG-island near the C9orf72 G□□repeat expansion in FTLD patients. *Human Molecular Genetics*, **2014**, 23, 5630-7 | 5.6 | 68 |
| 241 | Mutation analysis of CHCHD10 in different neurodegenerative diseases. *Brain*, **2015**, 138, e380 | 11.2 | 67 |
| 240 | Innate immune system and inflammation in Alzheimer's disease: from pathogenesis to treatment. *NeuroImmunoModulation*, **2014**, 21, 79-87 | 2.5 | 66 |
| 239 | Epigenetic modulation of BDNF gene in patients with major depressive disorder. *Biological Psychiatry*, **2013**, 73, e6-7 | 7.9 | 66 |
| 238 | Osteopontin is increased in the cerebrospinal fluid of patients with Alzheimer's disease and its levels correlate with cognitive decline. *Journal of Alzheimerjs Disease*, **2010**, 19, 1143-8 | 4.3 | 66 |
| 237 | Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration. *Journal of Neurology*, **2008**, 255, 539-44 | 5.5 | 64 |
| 236 | Old and new acetylcholinesterase inhibitors for Alzheimer's disease. *Expert Opinion on Investigational Drugs*, **2016**, 25, 1181-7 | 5.9 | 63 |
| 235 | Pioglitazone for the treatment of Alzheimer's disease. *Expert Opinion on Investigational Drugs*, **2017**, 26, 97-101 | 5.9 | 62 |
| 234 | Lack of adiponectin leads to increased lymphocyte activation and increased disease severity in a mouse model of multiple sclerosis. *European Journal of Immunology*, **2013**, 43, 2089-100 | 6.1 | 62 |
| 233 | Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. *Lancet Neurology, The*, **2018**, 17, 548-558 | 24.1 | 60 |
| 232 | Loss of function mutations in the progranulin gene are related to pro-inflammatory cytokine dysregulation in frontotemporal lobar degeneration patients. *Journal of Neuroinflammation*, **2011**, 8, 65 | 10.1 | 60 |
| 231 | Early onset behavioral variant frontotemporal dementia due to the C9ORF72 hexanucleotide repeat expansion: psychiatric clinical presentations. *Journal of Alzheimerjs Disease*, **2012**, 31, 447-52 | 4.3 | 59 |
| 230 | From genotype to phenotype: two cases of genetic frontotemporal lobar degeneration with premorbid bipolar disorder. *Journal of Alzheimerjs Disease*, **2011**, 27, 791-7 | 4.3 | 59 |
| 229 | Progranulin genetic variations in frontotemporal lobar degeneration: evidence for low mutation frequency in an Italian clinical series. *Neurogenetics*, **2008**, 9, 197-205 | 3 | 59 |
| 228 | Phenotypic heterogeneity of the GRN Asp22fs mutation in a large Italian kindred. *Journal of Alzheimerjs Disease*, **2011**, 24, 253-9 | 4.3 | 57 |
| 227 | Inclusion body myopathy and frontotemporal dementia caused by a novel VCP mutation. *Neurobiology of Aging*, **2009**, 30, 752-8 | 5.6 | 55 |

| | | | |
|---|---|---|---|
| 226 | Physical activity reduces the risk of dementia in mild cognitive impairment subjects: a cohort study. *Journal of Alzheimerjs Disease*, **2014**, 39, 833-9 | 4.3 | 53 |
| 225 | Expression and Genetic Analysis of MicroRNAs Involved in Multiple Sclerosis. *International Journal of Molecular Sciences*, **2013**, 14, 4375-84 | 6.3 | 53 |
| 224 | Intrathecal chemokine levels in Alzheimer disease and frontotemporal lobar degeneration. *Neurology*, **2006**, 66, 146-7 | 6.5 | 53 |
| 223 | Psychiatric symptoms in frontotemporal dementia: epidemiology, phenotypes, and differential diagnosis. *Biological Psychiatry*, **2015**, 78, 684-92 | 7.9 | 52 |
| 222 | Expression of the transcription factor Sp1 and its regulatory hsa-miR-29b in peripheral blood mononuclear cells from patients with Alzheimer's disease. *Journal of Alzheimerjs Disease*, **2013**, 35, 487-94 | 4.3 | 52 |
| 221 | Immunoproteasome LMP2 60HH variant alters MBP epitope generation and reduces the risk to develop multiple sclerosis in Italian female population. *PLoS ONE*, **2010**, 5, e9287 | 3.7 | 51 |
| 220 | CHCHD10 mutations in Italian patients with sporadic amyotrophic lateral sclerosis. *Brain*, **2015**, 138, e372 | 11.2 | 49 |
| 219 | Rs5848 variant influences GRN mRNA levels in brain and peripheral mononuclear cells in patients with Alzheimer's disease. *Journal of Alzheimerjs Disease*, **2009**, 18, 603-12 | 4.3 | 49 |
| 218 | The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer's disease: a meta-analysis study. *Journal of Alzheimerjs Disease*, **2010**, 22, 247-55 | 4.3 | 48 |
| 217 | Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2015**, 16, 86-91 | 3.6 | 47 |
| 216 | An emerging role for long non-coding RNA dysregulation in neurological disorders. *International Journal of Molecular Sciences*, **2013**, 14, 20427-42 | 6.3 | 47 |
| 215 | Disease-modifying drugs in Alzheimer's disease. *Drug Design, Development and Therapy*, **2013**, 7, 1471-8 | 4.4 | 47 |
| 214 | HLA-class I markers and multiple sclerosis susceptibility in the Italian population. *Genes and Immunity*, **2010**, 11, 173-80 | 4.4 | 47 |
| 213 | Recognition of viral and self-antigens by T1 and T1/T17 central memory cells in patients with multiple sclerosis reveals distinct roles in immune surveillance and relapses. *Journal of Allergy and Clinical Immunology*, **2017**, 140, 797-808 | 11.5 | 46 |
| 212 | Weight Loss Predicts Progression of Mild Cognitive Impairment to Alzheimer's Disease. *PLoS ONE*, **2016**, 11, e0151710 | 3.7 | 46 |
| 211 | Role of hnRNP-A1 and miR-590-3p in neuronal death: genetics and expression analysis in patients with Alzheimer disease and frontotemporal lobar degeneration. *Rejuvenation Research*, **2011**, 14, 275-81 | 2.6 | 45 |
| 210 | Epigenetic regulation of fatty acid amide hydrolase in Alzheimer disease. *PLoS ONE*, **2012**, 7, e39186 | 3.7 | 45 |
| 209 | C9ORF72 hexanucleotide repeat expansion is a rare cause of schizophrenia. *Neurobiology of Aging*, **2014**, 35, 1214.e7-1214.e10 | 5.6 | 44 |

| | | | |
|---|---|---|---|
| 208 | The Enigmatic Role of Viruses in Multiple Sclerosis: Molecular Mimicry or Disturbed Immune Surveillance?. *Trends in Immunology*, **2017**, 38, 498-512 | 14.4 | 43 |
| 207 | White matter hyperintensities are seen only in mutation carriers in the GENFI cohort. *NeuroImage: Clinical*, **2017**, 15, 171-180 | 5.3 | 43 |
| 206 | MicroRNAs as active players in the pathogenesis of multiple sclerosis. *International Journal of Molecular Sciences*, **2012**, 13, 13227-39 | 6.3 | 43 |
| 205 | The human astrocytoma cell line U373MG produces monocyte chemotactic protein (MCP)-1 upon stimulation with beta-amyloid protein. *Neuroscience Letters*, **2000**, 283, 177-80 | 3.3 | 43 |
| 204 | Cerebrospinal fluid biomarkers in Progranulin mutations carriers. *Journal of Alzheimerjs Disease*, **2011**, 27, 781-90 | 4.3 | 42 |
| 203 | An APOE haplotype associated with decreased ε4 expression increases the risk of late onset Alzheimer's disease. *Journal of Alzheimerjs Disease*, **2011**, 24, 235-45 | 4.3 | 42 |
| 202 | A functional variant in ERAP1 predisposes to multiple sclerosis. *PLoS ONE*, **2012**, 7, e29931 | 3.7 | 41 |
| 201 | Is M129V of PRNP gene associated with Alzheimer's disease? A case-control study and a meta-analysis. *Neurobiology of Aging*, **2006**, 27, 770.e1-770.e5 | 5.6 | 40 |
| 200 | Pharmacogenomics in Alzheimer's disease: a genome-wide association study of response to cholinesterase inhibitors. *Neurobiology of Aging*, **2013**, 34, 1711.e7-13 | 5.6 | 36 |
| 199 | Immunotherapy against amyloid pathology in Alzheimer's disease. *Journal of the Neurological Sciences*, **2013**, 333, 50-4 | 3.2 | 36 |
| 198 | The SIRT2 polymorphism rs10410544 and risk of Alzheimer's disease in two Caucasian case-control cohorts. *Alzheimerjs and Dementia*, **2013**, 9, 392-9 | 1.2 | 36 |
| 197 | Inflammation in dry eye associated with rheumatoid arthritis: cytokine and in vivo confocal microscopy study. *Innate Immunity*, **2013**, 19, 420-7 | 2.7 | 36 |
| 196 | Treatment of Alzheimer's disease: symptomatic and disease-modifying approaches. *Current Aging Science*, **2010**, 3, 46-56 | 2.2 | 36 |
| 195 | Variations of the perforin gene in patients with multiple sclerosis. *Genes and Immunity*, **2008**, 9, 438-44 | 4.4 | 35 |
| 194 | Inflammatory molecules in Frontotemporal Dementia: cerebrospinal fluid signature of progranulin mutation carriers. *Brain, Behavior, and Immunity*, **2015**, 49, 182-7 | 16.6 | 34 |
| 193 | A genome-wide screening and SNPs-to-genes approach to identify novel genetic risk factors associated with frontotemporal dementia. *Neurobiology of Aging*, **2015**, 36, 2904.e13-26 | 5.6 | 34 |
| 192 | Does vascular burden contribute to the progression of mild cognitive impairment to dementia?. *Dementia and Geriatric Cognitive Disorders*, **2012**, 34, 235-43 | 2.6 | 34 |
| 191 | Novel exon 1 progranulin gene variant in Alzheimer's disease. *European Journal of Neurology*, **2008**, 15, 1111-7 | 6 | 34 |

| | | | |
|---|---|---|---|
| 190 | Influence of the Glu298Asp polymorphism of NOS3 on age at onset and homocysteine levels in AD patients. *Neurobiology of Aging*, **2005**, 26, 789-94 | 5.6 | 33 |
| 189 | Comparison of arterial spin labeling registration strategies in the multi-center GENetic frontotemporal dementia initiative (GENFI). *Journal of Magnetic Resonance Imaging*, **2018**, 47, 131-140 | 5.6 | 32 |
| 188 | Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study. *Brain*, **2017**, 140, 1784-1791 | 11.2 | 31 |
| 187 | Role of Genetics and Epigenetics in the Pathogenesis of Alzheimer's Disease and Frontotemporal Dementia. *Journal of Alzheimerjs Disease*, **2018**, 62, 913-932 | 4.3 | 31 |
| 186 | Screening of the PFN1 gene in sporadic amyotrophic lateral sclerosis and in frontotemporal dementia. *Neurobiology of Aging*, **2013**, 34, 1517.e9-10 | 5.6 | 31 |
| 185 | Frontotemporal lobar degeneration: current knowledge and future challenges. *Journal of Neurology*, **2012**, 259, 2278-86 | 5.5 | 31 |
| 184 | Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in Alzheimer's disease patients. *Journal of Alzheimerjs Disease*, **2012**, 30, 745-9 | 4.3 | 31 |
| 183 | CSF □amyloid and white matter damage: a new perspective on Alzheimer's disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2018**, 89, 352-357 | 5.5 | 30 |
| 182 | CCR2-64I polymorphism and CCR5Delta32 deletion in patients with Alzheimer's disease. *Journal of the Neurological Sciences*, **2004**, 225, 79-83 | 3.2 | 30 |
| 181 | Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. *Neurobiology of Aging*, **2018**, 62, 245.e9-245.e12 | 5.6 | 30 |
| 180 | Extracellular proteasome-osteopontin circuit regulates cell migration with implications in multiple sclerosis. *Scientific Reports*, **2017**, 7, 43718 | 4.9 | 29 |
| 179 | Hemodynamic and Anatomic Variations Require an Adaptable Approach during Intra-Arterial Chemotherapy for Intraocular Retinoblastoma: Alternative Routes, Strategies, and Follow-Up. *American Journal of Neuroradiology*, **2016**, 37, 1289-95 | 4.4 | 29 |
| 178 | Heterosexual pedophilia in a frontotemporal dementia patient with a mutation in the progranulin gene. *Biological Psychiatry*, **2011**, 70, e43-4 | 7.9 | 29 |
| 177 | Pin1 contribution to Alzheimer's disease: transcriptional and epigenetic mechanisms in patients with late-onset Alzheimer's disease. *Neurodegenerative Diseases*, **2012**, 10, 207-11 | 2.3 | 28 |
| 176 | Genetics of frontotemporal lobar degeneration. *Frontiers in Neurology*, **2012**, 3, 52 | 4.1 | 28 |
| 175 | Association of a NOS1 promoter repeat with Alzheimer's disease. *Neurobiology of Aging*, **2008**, 29, 1359-65 | 5.6 | 28 |
| 174 | Defining the association of TMEM106B variants among frontotemporal lobar degeneration patients with GRN mutations and□C9orf72 repeat expansions. *Neurobiology of Aging*, **2014**, 35, 2658.e1-2658.e5 | 5.6 | 27 |
| 173 | Progranulin gene variability and plasma levels in bipolar disorder and schizophrenia. *PLoS ONE*, **2012**, 7, e32164 | 3.7 | 27 |

| | | | |
|---|---|---|---|
| 172 | A novel MAPT mutation associated with the clinical phenotype of progressive nonfluent aphasia. *Journal of Alzheimerjs Disease*, **2011**, 26, 19-26 | 4.3 | 27 |
| 171 | GRN variability contributes to sporadic frontotemporal lobar degeneration. *Journal of Alzheimerjs Disease*, **2010**, 19, 171-7 | 4.3 | 27 |
| 170 | Menopausal transition: a possible risk factor for brain pathologic events. *Neurobiology of Aging*, **2009**, 30, 71-80 | 5.6 | 27 |
| 169 | Inducible nitric oxide synthase (iNOS) in immune-mediated demyelination and Wallerian degeneration of the rat peripheral nervous system. *Experimental Neurology*, **2004**, 187, 350-8 | 5.7 | 27 |
| 168 | Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis. *Journal of Neuroimmunology*, **2016**, 299, 81-83 | 3.5 | 27 |
| 167 | Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. *Neurology* , **2014**, 83, 1210-6 | 6.5 | 26 |
| 166 | Possible association between SNAP-25 single nucleotide polymorphisms and alterations of categorical fluency and functional MRI parameters in Alzheimer's disease. *Journal of Alzheimerjs Disease*, **2014**, 42, 1015-28 | 4.3 | 26 |
| 165 | Incomplete penetrance of the C9ORF72 hexanucleotide repeat expansions: frequency in a cohort of geriatric non-demented subjects. *Journal of Alzheimerjs Disease*, **2014**, 39, 19-22 | 4.3 | 26 |
| 164 | C9ORF72 hexanucleotide repeat expansion as a rare cause of bipolar disorder. *Bipolar Disorders*, **2014**, 16, 448-9 | 3.8 | 26 |
| 163 | Current understanding on the role of standard and immunoproteasomes in inflammatory/immunological pathways of multiple sclerosis. *Autoimmune Diseases*, **2014**, 2014, 739705 | 2.9 | 26 |
| 162 | Founder effect and estimation of the age of the Progranulin Thr272fs mutation in 14 Italian pedigrees with frontotemporal lobar degeneration. *Neurobiology of Aging*, **2011**, 32, 555.e1-8 | 5.6 | 26 |
| 161 | Gender-specific influence of the chromosome 16 chemokine gene cluster on the susceptibility to Multiple Sclerosis. *Journal of the Neurological Sciences*, **2008**, 267, 86-90 | 3.2 | 26 |
| 160 | Growth Arrest Specific 6 Concentration is Increased in the Cerebrospinal Fluid of Patients with Alzheimer's Disease. *Journal of Alzheimerjs Disease*, **2017**, 55, 59-65 | 4.3 | 26 |
| 159 | Reversible Mild Cognitive Impairment: The Role of Comorbidities at Baseline Evaluation. *Journal of Alzheimerjs Disease*, **2016**, 51, 57-67 | 4.3 | 26 |
| 158 | ABCA1- and ABCG1-mediated cholesterol efflux capacity of cerebrospinal fluid is impaired in Alzheimer's disease. *Journal of Lipid Research*, **2019**, 60, 1449-1456 | 6.3 | 25 |
| 157 | Progranulin gene (GRN) promoter methylation is increased in patients with sporadic frontotemporal lobar degeneration. *Neurological Sciences*, **2013**, 34, 899-903 | 3.5 | 25 |
| 156 | The impact of osteopontin gene variations on multiple sclerosis development and progression. *Clinical and Developmental Immunology*, **2012**, 2012, 212893 | | 25 |
| 155 | The T-786C NOS3 polymorphism in Alzheimer's disease: association and influence on gene expression. *Neuroscience Letters*, **2005**, 382, 300-3 | 3.3 | 25 |

| | | | |
|---|---|---|---|
| 154 | Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer's Disease. *Journal of Alzheimerjs Disease*, **2017**, 55, 315-320 | 4.3 | 25 |
| 153 | The loss of macular ganglion cells begins from the early stages of disease and correlates with brain atrophy in multiple sclerosis patients. *Multiple Sclerosis Journal*, **2019**, 25, 31-38 | 5 | 25 |
| 152 | Distinct patterns of brain atrophy in Genetic Frontotemporal Dementia Initiative (GENFI) cohort revealed by visual rating scales. *Alzheimerjs Research and Therapy*, **2018**, 10, 46 | 9 | 24 |
| 151 | Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. *Neurobiology of Aging*, **2019**, 77, 169-177 | 5.6 | 24 |
| 150 | CSF □amyloid as a putative biomarker of disease progression in multiple sclerosis. *Multiple Sclerosis Journal*, **2017**, 23, 1085-1091 | 5 | 23 |
| 149 | Genetic analysis of matrin 3 gene in French amyotrophic lateral sclerosis patients and frontotemporal lobar degeneration with amyotrophic lateral sclerosis patients. *Neurobiology of Aging*, **2014**, 35, 2882.e13-2882.e15 | 5.6 | 23 |
| 148 | The role of the innate immune system in Alzheimer's disease and frontotemporal lobar degeneration: an eye on microglia. *Clinical and Developmental Immunology*, **2013**, 2013, 939786 | | 22 |
| 147 | Interleukin-6 plasma level increases with age in an Italian elderly population ("The Treviso Longeva"-Trelong-study) with a sex-specific contribution of rs1800795 polymorphism. *Age*, **2009**, 31, 155-62 | | 22 |
| 146 | Preliminary evidence that VEGF genetic variability confers susceptibility to frontotemporal lobar degeneration. *Rejuvenation Research*, **2008**, 11, 773-80 | 2.6 | 22 |
| 145 | A novel polymorphism in SEL1L confers susceptibility to Alzheimer's disease. *Neuroscience Letters*, **2006**, 398, 53-8 | 3.3 | 22 |
| 144 | Cerebrospinal fluid progranulin levels in patients with different multiple sclerosis subtypes. *Neuroscience Letters*, **2010**, 469, 234-6 | 3.3 | 21 |
| 143 | MDC/CCL22 intrathecal levels in patients with multiple sclerosis. *Multiple Sclerosis Journal*, **2008**, 14, 547-9 | 5 | 21 |
| 142 | Synergistic effect of beta-amyloid protein and interferon gamma on nitric oxide production by C2C12 muscle cells. *Brain*, **2000**, 123 ( Pt 2), 374-9 | 11.2 | 21 |
| 141 | Role of OLR1 and its regulating hsa-miR369-3p in Alzheimer's disease: genetics and expression analysis. *Journal of Alzheimerjs Disease*, **2011**, 26, 787-93 | 4.3 | 20 |
| 140 | The NOS3 G894T (Glu298Asp) polymorphism is a risk factor for frontotemporal lobar degeneration. *European Journal of Neurology*, **2009**, 16, 37-42 | 6 | 20 |
| 139 | ICOS gene haplotypes correlate with IL10 secretion and multiple sclerosis evolution. *Journal of Neuroimmunology*, **2007**, 186, 193-8 | 3.5 | 20 |
| 138 | Intra-arterial chemotherapy with melphalan for intraocular retinoblastoma. *British Journal of Ophthalmology*, **2013**, 97, 1219-21 | 5.5 | 19 |
| 137 | The H1 haplotype of the tau gene (MAPT) is associated with mild cognitive impairment. *Journal of Alzheimerjs Disease*, **2010**, 19, 909-14 | 4.3 | 19 |

| | | | |
|---|---|---|---|
| 136 | A trans-specific polymorphism in ZC3HAV1 is maintained by long-standing balancing selection and may confer susceptibility to multiple sclerosis. *Molecular Biology and Evolution*, **2012**, 29, 1599-613 | 8.3 | 19 |
| 135 | A sequence variation in the MOG gene is involved in multiple sclerosis susceptibility in Italy. *Genes and Immunity*, **2008**, 9, 7-15 | 4.4 | 19 |
| 134 | CXCL10 haplotypes and multiple sclerosis: association and correlation with clinical course. *European Journal of Neurology*, **2007**, 14, 162-7 | 6 | 19 |
| 133 | The leukocyte expression of CD36 is low in patients with Alzheimer's disease and mild cognitive impairment. *Neurobiology of Aging*, **2007**, 28, 515-8 | 5.6 | 19 |
| 132 | Fluid biomarkers in frontotemporal dementia: past, present and future. *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**, 92, 204-215 | 5.5 | 19 |
| 131 | The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. *NeuroImage*, **2019**, 189, 645-654 | 7.9 | 18 |
| 130 | Analysis of genes, pathways and networks involved in disease severity and age at onset in primary-progressive multiple sclerosis. *Multiple Sclerosis Journal*, **2015**, 21, 1431-42 | 5 | 18 |
| 129 | A low-molecular-weight ferroxidase is increased in the CSF of sCJD cases: CSF ferroxidase and transferrin as diagnostic biomarkers for sCJD. *Antioxidants and Redox Signaling*, **2013**, 19, 1662-75 | 8.4 | 18 |
| 128 | Absence of TREM2 polymorphisms in patients with Alzheimer's disease and Frontotemporal Lobar Degeneration. *Neuroscience Letters*, **2007**, 411, 133-7 | 3.3 | 18 |
| 127 | Regulation of gene transcription in bipolar disorders: Role of DNA methylation in the relationship between prodynorphin and brain derived neurotrophic factor. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2018**, 82, 314-321 | 5.5 | 17 |
| 126 | Distinct Neuroanatomical Correlates of Neuropsychiatric Symptoms in the Three Main Forms of Genetic Frontotemporal Dementia in the GENFI Cohort. *Journal of Alzheimerjs Disease*, **2018**, 65, 147-163 | 4.3 | 17 |
| 125 | Identification of a new susceptibility variant for multiple sclerosis in OAS1 by population genetics analysis. *Human Genetics*, **2012**, 131, 87-97 | 6.3 | 17 |
| 124 | GSK3 genetic variability in patients with Multiple Sclerosis. *Neuroscience Letters*, **2011**, 497, 46-8 | 3.3 | 17 |
| 123 | MCP-1 A-2518G polymorphism: effect on susceptibility for frontotemporal lobar degeneration and on cerebrospinal fluid MCP-1 levels. *Journal of Alzheimerjs Disease*, **2009**, 17, 125-33 | 4.3 | 17 |
| 122 | Chemokine network in multiple sclerosis: role in pathogenesis and targeting for future treatments. *Expert Review of Neurotherapeutics*, **2004**, 4, 439-53 | 4.3 | 17 |
| 121 | Iron in Frontotemporal Lobar Degeneration: A New Subcortical Pathological Pathway?. *Neurodegenerative Diseases*, **2016**, 16, 172-8 | 2.3 | 16 |
| 120 | Gene promoter methylation and expression of Pin1 differ between patients with frontotemporal dementia and Alzheimer's disease. *Journal of the Neurological Sciences*, **2016**, 362, 283-6 | 3.2 | 16 |
| 119 | Is HCRTR2 a genetic risk factor for Alzheimer's disease?. *Dementia and Geriatric Cognitive Disorders*, **2014**, 38, 245-53 | 2.6 | 16 |

| | | | |
|---|---|---|---|
| 118 | Possible influence of a non-synonymous polymorphism located in the NGF precursor on susceptibility to late-onset Alzheimer's disease and mild cognitive impairment. *Journal of Alzheimerjs Disease*, **2012**, 29, 699-705 | 4.3 | 16 |
| 117 | Clinical phenotypes and genetic biomarkers of FTLD. *Journal of Neural Transmission*, **2012**, 119, 851-60 | 4.3 | 16 |
| 116 | IP-10 serum levels are not increased in mild cognitive impairment and Alzheimer's disease. *European Journal of Neurology*, **2007**, 14, e3-4 | 6 | 16 |
| 115 | Neuronal nitric oxide synthase C276T polymorphism increases the risk for frontotemporal lobar degeneration. *European Journal of Neurology*, **2008**, 15, 77-81 | 6 | 16 |
| 114 | Presenilin-1 mutation E318G and familial Alzheimer's disease in the Italian population. *Neurobiology of Aging*, **2007**, 28, 1682-8 | 5.6 | 16 |
| 113 | Pharmacological Management of Psychiatric Symptoms in Frontotemporal Dementia: A Systematic Review. *Journal of Geriatric Psychiatry and Neurology*, **2017**, 30, 162-169 | 3.8 | 15 |
| 112 | Progranulin gene variability influences the risk for bipolar I disorder, but not bipolar II disorder. *Bipolar Disorders*, **2014**, 16, 769-72 | 3.8 | 15 |
| 111 | Novel evidence of phenotypical variability in the hexanucleotide repeat expansion in chromosome 9. *Journal of Alzheimerjs Disease*, **2013**, 35, 455-62 | 4.3 | 15 |
| 110 | Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. *Brain Research*, **2010**, 1333, 64-71 | 3.7 | 15 |
| 109 | Candidate gene analysis of IP-10 gene in patients with Alzheimer's disease. *Neuroscience Letters*, **2006**, 404, 217-21 | 3.3 | 15 |
| 108 | E-selectin A561C and G98T polymorphisms influence susceptibility and course of multiple sclerosis. *Journal of Neuroimmunology*, **2005**, 165, 201-5 | 3.5 | 15 |
| 107 | Association of neuronal nitric oxide synthase C276T polymorphism with Alzheimer's disease. *Journal of Neurology*, **2005**, 252, 985-6 | 5.5 | 15 |
| 106 | CSF pro-orexin and amyloid-β38 expression in Alzheimer's disease and frontotemporal dementia. *Neurobiology of Aging*, **2018**, 72, 171-176 | 5.6 | 15 |
| 105 | Exploring the role of BDNF DNA methylation and hydroxymethylation in patients with obsessive compulsive disorder. *Journal of Psychiatric Research*, **2019**, 114, 17-23 | 5.2 | 14 |
| 104 | Novel missense progranulin gene mutation associated with the semantic variant of primary progressive aphasia. *Journal of Alzheimerjs Disease*, **2013**, 36, 415-20 | 4.3 | 14 |
| 103 | No major progranulin genetic variability contribution to disease etiopathogenesis in an ALS Italian cohort. *Neurobiology of Aging*, **2011**, 32, 1157-8 | 5.6 | 14 |
| 102 | Serotonin transporter gene polymorphic element 5-HTTLPR increases the risk of sporadic Parkinson's disease in Italy. *European Neurology*, **2009**, 62, 120-3 | 2.1 | 14 |
| 101 | SORL1 Gene is Associated with the Conversion from Mild Cognitive Impairment to Alzheimer's Disease. *Journal of Alzheimerjs Disease*, **2015**, 46, 771-6 | 4.3 | 13 |

| | | | |
|---|---|---|---|
| 100 | Idalopirdine as a treatment for Alzheimer's disease. *Expert Opinion on Investigational Drugs*, **2015**, 24, 981-7 | 5.9 | 13 |
| 99 | GRN Thr272fs clinical heterogeneity: a case with atypical late onset presenting with a dementia with Lewy bodies phenotype. *Journal of Alzheimerjs Disease*, **2013**, 35, 669-74 | 4.3 | 13 |
| 98 | Gender effects on plasma PGRN levels in patients with Alzheimer's disease: a preliminary study. *Journal of Alzheimerjs Disease*, **2013**, 35, 313-8 | 4.3 | 13 |
| 97 | Progranulin gene variability increases the risk for primary progressive multiple sclerosis in males. *Genes and Immunity*, **2010**, 11, 497-503 | 4.4 | 13 |
| 96 | Analysis of the genes coding for subunit 10 and 15 of cytochrome c oxidase in Alzheimer's disease. *Journal of Neural Transmission*, **2009**, 116, 1635-41 | 4.3 | 13 |
| 95 | A 66-year-old patient with vanishing white matter disease due to the p.Ala87Val EIF2B3 mutation. *Neurology*, **2012**, 79, 2077-8 | 6.5 | 13 |
| 94 | P-selectin glycoprotein ligand-1 variable number of tandem repeats (VNTR) polymorphism in patients with multiple sclerosis. *Neuroscience Letters*, **2005**, 388, 149-52 | 3.3 | 13 |
| 93 | Progressive, isolated language disturbance: its significance in a 65-year-old-man. A case report with implications for treatment and review of literature. *Journal of the Neurological Sciences*, **2006**, 240, 45-51 | 3.2 | 13 |
| 92 | SELPLG and SELP single-nucleotide polymorphisms in multiple sclerosis. *Neuroscience Letters*, **2006**, 394, 92-6 | 3.3 | 13 |
| 91 | Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease. *Neurobiology of Aging*, **2020**, 87, 139.e1-139.e7 | 5.6 | 13 |
| 90 | Clinical and MRI correlates of disease progression in a case of nonfluent/agrammatic variant of primary progressive aphasia due to progranulin (GRN) Cys157LysfsX97 mutation. *Journal of the Neurological Sciences*, **2014**, 342, 167-72 | 3.2 | 12 |
| 89 | Evidence of pre-synaptic dopaminergic deficit in a patient with a novel progranulin mutation presenting with atypical parkinsonism. *Journal of Alzheimerjs Disease*, **2014**, 38, 747-52 | 4.3 | 12 |
| 88 | Study of thyroid hormone receptor alpha gene polymorphisms on Alzheimer's disease. *Neurobiology of Aging*, **2011**, 32, 624-30 | 5.6 | 12 |
| 87 | DCUN1D1 is a risk factor for frontotemporal lobar degeneration. *European Journal of Neurology*, **2009**, 16, 870-3 | 6 | 12 |
| 86 | PRNP P39L Variant is a Rare Cause of Frontotemporal Dementia in Italian Population. *Journal of Alzheimerjs Disease*, **2016**, 50, 353-7 | 4.3 | 12 |
| 85 | CHRNA7 Gene and Response to Cholinesterase Inhibitors in an Italian Cohort of Alzheimer's Disease Patients. *Journal of Alzheimerjs Disease*, **2016**, 52, 1203-8 | 4.3 | 12 |
| 84 | Lag-time in Alzheimer's disease patients: a potential plasmatic oxidative stress marker associated with ApoE4 isoform. *Immunity and Ageing*, **2019**, 16, 7 | 9.7 | 11 |
| 83 | PICALM Gene Methylation in Blood of Alzheimer's Disease Patients Is Associated with Cognitive Decline. *Journal of Alzheimerjs Disease*, **2018**, 65, 283-292 | 4.3 | 11 |

| | | | |
|---|---|---|---|
| 82 | Progranulin as a therapeutic target for dementia. *Expert Opinion on Therapeutic Targets*, **2018**, 22, 579-585 | 3.4 | 11 |
| 81 | Association between DPP6 polymorphism and the risk of progressive multiple sclerosis in Northern and Southern Europeans. *Neuroscience Letters*, **2012**, 530, 155-60 | 3.3 | 11 |
| 80 | Genetic variation in the choline O-acetyltransferase gene in depression and Alzheimer's disease: the VITA and Milano studies. *Journal of Psychiatric Research*, **2011**, 45, 1250-6 | 5.2 | 11 |
| 79 | The serotonin transporter promoter polymorphic region is not a risk factor for Alzheimer's disease related behavioral disturbances. *Journal of Alzheimerjs Disease*, **2009**, 18, 125-30 | 4.3 | 11 |
| 78 | The progranulin (GRN) Cys157LysfsX97 mutation is associated with nonfluent variant of primary progressive aphasia clinical phenotype. *Journal of Alzheimerjs Disease*, **2012**, 28, 759-63 | 4.3 | 11 |
| 77 | The CST3 B haplotype is associated with frontotemporal lobar degeneration. *European Journal of Neurology*, **2010**, 17, 143-6 | 6 | 11 |
| 76 | Structural and metabolic cerebral alterations between elderly bipolar disorder and behavioural variant frontotemporal dementia: A combined MRI-PET study. *Australian and New Zealand Journal of Psychiatry*, **2019**, 53, 413-423 | 2.6 | 11 |
| 75 | Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic C9orf72 Repeat Expansion Adult Carriers. *Annals of Neurology*, **2020**, 88, 113-122 | 9.4 | 11 |
| 74 | Progranulin genetic polymorphisms influence progression of disability and relapse recovery in multiple sclerosis. *Multiple Sclerosis Journal*, **2016**, 22, 1007-12 | 5 | 10 |
| 73 | Progress in Alzheimer's disease research in the last year. *Journal of Neurology*, **2013**, 260, 1936-41 | 5.5 | 10 |
| 72 | The Italian dementia with Lewy bodies study group (DLB-SINdem): toward a standardization of clinical procedures and multicenter cohort studies design. *Neurological Sciences*, **2017**, 38, 83-91 | 3.5 | 10 |
| 71 | A study of the association between the ADAM12 and SH3PXD2A (SH3MD1) genes and Alzheimer's disease. *Neuroscience Letters*, **2010**, 468, 1-2 | 3.3 | 10 |
| 70 | Alpha1-antichymotrypsin induces TNF-alpha production and NF-kappaB activation in the murine N9 microglial cell line. *Neuroscience Letters*, **2009**, 467, 40-2 | 3.3 | 10 |
| 69 | Role of VEGF gene variability in longevity: a lesson from the Italian population. *Neurobiology of Aging*, **2008**, 29, 1917-22 | 5.6 | 10 |
| 68 | Non-progressive leukoencephalopathy with bilateral anterior temporal cysts: a case report and review of the literature. *Brain and Development*, **2005**, 27, 73-7 | 2.2 | 10 |
| 67 | Spatiotemporal analysis for detection of pre-symptomatic shape changes in neurodegenerative diseases: Initial application to the GENFI cohort. *NeuroImage*, **2019**, 188, 282-290 | 7.9 | 10 |
| 66 | Profiling of ubiquitination pathway genes in peripheral cells from patients with frontotemporal dementia due to C9ORF72 and GRN mutations. *International Journal of Molecular Sciences*, **2015**, 16, 1385-94 | 6.3 | 9 |
| 65 | Association of HLA class I markers with multiple sclerosis in the Italian and UK population: evidence of two independent protective effects. *Journal of Medical Genetics*, **2011**, 48, 485-92 | 5.8 | 9 |

| | | | |
|---|---|---|---|
| 64 | Candidate gene analysis of semaphorins in patients with Alzheimer's disease. *Neurological Sciences*, **2010**, 31, 169-73 | 3.5 | 9 |
| 63 | Lack of replication of KIF1B gene in an Italian primary progressive multiple sclerosis cohort. *European Journal of Neurology*, **2010**, 17, 740-5 | 6 | 9 |
| 62 | Untangling Extracellular Proteasome-Osteopontin Circuit Dynamics in Multiple Sclerosis. *Cells*, **2019**, 8, | 7.9 | 8 |
| 61 | Microtubule defects in mesenchymal stromal cells distinguish patients with Progressive Supranuclear Palsy. *Journal of Cellular and Molecular Medicine*, **2018**, 22, 2670-2679 | 5.6 | 8 |
| 60 | Comparison of β-microglobulin serum level between Alzheimer's patients, cognitive healthy and mild cognitive impaired individuals. *Biomarkers*, **2018**, 23, 603-608 | 2.6 | 8 |
| 59 | Italian Frontotemporal Dementia Network (FTD Group-SINDEM): sharing clinical and diagnostic procedures in Frontotemporal Dementia in Italy. *Neurological Sciences*, **2015**, 36, 751-7 | 3.5 | 8 |
| 58 | Is KIF24 a genetic risk factor for Frontotemporal Lobar Degeneration?. *Neuroscience Letters*, **2010**, 482, 240-4 | 3.3 | 8 |
| 57 | Absence of TARDBP gene mutations in an italian series of patients with frontotemporal lobar degeneration. *Dementia and Geriatric Cognitive Disorders*, **2009**, 28, 239-43 | 2.6 | 8 |
| 56 | Association of the CBLB gene with multiple sclerosis: new evidence from a replication study in an Italian population. *Journal of Medical Genetics*, **2011**, 48, 210-1 | 5.8 | 8 |
| 55 | Association study to evaluate the serotonin transporter and apolipoprotein E genes in frontotemporal lobar degeneration in Italy. *Journal of Human Genetics*, **2008**, 53, 1029-1033 | 4.3 | 8 |
| 54 | Neuroimaging Correlates of Frontotemporal Dementia Associated with SQSTM1 Mutations. *Journal of Alzheimerjs Disease*, **2016**, 53, 303-13 | 4.3 | 8 |
| 53 | Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. *Journal of Alzheimerjs Disease*, **2017**, 56, 543-555 | 4.3 | 7 |
| 52 | Sciatic endometriosis presenting as periodic (catamenial) sciatic radiculopathy. *Journal of Neurology* , **2012**, 259, 1470-1 | 5.5 | 7 |
| 51 | Candidate gene analysis of selectin cluster in patients with multiple sclerosis. *Journal of Neurology*, **2009**, 256, 832-3 | 5.5 | 7 |
| 50 | Clinical, neuropathological, and genetic characteristics of the novel IVS9+1delG GRN mutation in a patient with frontotemporal dementia. *Journal of Alzheimerjs Disease*, **2012**, 30, 83-90 | 4.3 | 7 |
| 49 | Is the ornithine transcarbamylase gene a genetic determinant of Alzheimer's disease?. *Neuroscience Letters*, **2009**, 449, 76-80 | 3.3 | 7 |
| 48 | Failure to replicate an association of rs5984894 SNP in the PCDH11X gene in a collection of 1,222 Alzheimer's disease affected patients. *Journal of Alzheimerjs Disease*, **2010**, 21, 385-8 | 4.3 | 7 |
| 47 | Serum folate concentrations in patients with cortical and subcortical dementias. *Neuroscience Letters*, **2007**, 420, 213-6 | 3.3 | 7 |

| | | | |
|---|---|---|---|
| 46 | The novel GRN g.1159_1160delTG mutation is associated with behavioral variant frontotemporal dementia. *Journal of Alzheimerjs Disease*, **2015**, 44, 277-82 | 4.3 | 6 |
| 45 | The Neuroanatomy of Somatoform Disorders: A Magnetic Resonance Imaging Study. *Psychosomatics*, **2019**, 60, 278-288 | 2.6 | 6 |
| 44 | Familial clustering in Italian progressive-onset and bout-onset multiple sclerosis. *Neurological Sciences*, **2014**, 35, 789-91 | 3.5 | 6 |
| 43 | Rapidly progressive primary progressive aphasia and parkinsonism with novel GRN mutation. *Movement Disorders*, **2017**, 32, 476-478 | 7 | 6 |
| 42 | Genetics and expression analysis of the specificity protein 4 gene (SP4) in patients with Alzheimer's disease and frontotemporal lobar degeneration. *Journal of Alzheimerjs Disease*, **2012**, 31, 537-42 | 4.3 | 6 |
| 41 | Polymorphisms in the LOC387715/ARMS2 putative gene and the risk for Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders*, **2008**, 26, 169-74 | 2.6 | 6 |
| 40 | Ball's concentric sclerosis: still to be considered as a variant of multiple sclerosis?. *Neurological Sciences*, **2015**, 36, 2277-80 | 3.5 | 5 |
| 39 | Non Fluent Variant of Primary Progressive Aphasia Due to the Novel GRN g.9543delA(IVS3-2delA) Mutation. *Journal of Alzheimerjs Disease*, **2016**, 54, 717-21 | 4.3 | 5 |
| 38 | C9ORF72 repeat expansion not detected in patients with multiple sclerosis. *Neurobiology of Aging*, **2014**, 35, 1213.e1-2 | 5.6 | 5 |
| 37 | Phenotypic variability associated with the C9ORF72 hexanucleotide repeat expansion: a sporadic case of frontotemporal lobar degeneration with prodromal hyposmia and predominant semantic deficits. *Journal of Alzheimerjs Disease*, **2014**, 40, 849-55 | 4.3 | 5 |
| 36 | CCL8/MCP-2 association analysis in patients with Alzheimer's disease and frontotemporal lobar degeneration. *Journal of Neurology*, **2009**, 256, 1379-81 | 5.5 | 5 |
| 35 | The functional MAOA-uVNTR promoter polymorphism in patients with frontotemporal dementia. *European Journal of Neurology*, **2008**, 15, 637-9 | 6 | 5 |
| 34 | Candidate gene analysis of SPARCL1 gene in patients with multiple sclerosis. *Neuroscience Letters*, **2007**, 425, 173-6 | 3.3 | 5 |
| 33 | Genetics and neurobiology of frontotemporal lobar degeneration. *Neurological Sciences*, **2006**, 27 Suppl 1, S32-4 | 3.5 | 5 |
| 32 | Inflammatory expression profile in peripheral blood mononuclear cells from patients with Nasu-Hakola Disease. *Cytokine*, **2019**, 116, 115-119 | 4 | 4 |
| 31 | Self-Awareness for Memory Impairment in Amnestic Mild Cognitive Impairment: A Longitudinal Study. *American Journal of Alzheimerjs Disease and Other Dementias*, **2017**, 32, 401-407 | 2.5 | 4 |
| 30 | Word and Picture Version of the Free and Cued Selective Reminding Test (FCSRT): Is There Any Difference?. *Journal of Alzheimerjs Disease*, **2018**, 61, 47-52 | 4.3 | 4 |
| 29 | A novel study and meta-analysis of the genetic variation of the serotonin transporter promoter in the italian population do not support a large effect on Alzheimer's disease risk. *International Journal of Alzheimerjs Disease*, **2011**, 2011, 312341 | 3.7 | 4 |

| | | | |
|---|---|---|---|
| 28 | Interaction between the APOE epsilon4 allele and the APH-1b c + 651T > G SNP in Alzheimer's disease. *Neurobiology of Aging*, **2008**, 29, 1494-501 | 5.6 | 4 |
| 27 | Usefulness of Multi-Parametric MRI for the Investigation of Posterior Cortical Atrophy. *PLoS ONE*, **2015**, 10, e0140639 | 3.7 | 4 |
| 26 | Cerebrospinal fluid glutamate changes in functional movement disorders. *Npj Parkinsonjs Disease*, **2020**, 6, 37 | 9.7 | 4 |
| 25 | The distinct roles of monoamines in multiple sclerosis: A bridge between the immune and nervous systems?. *Brain, Behavior, and Immunity*, **2021**, 94, 381-391 | 16.6 | 4 |
| 24 | Epigenetic regulatory modifications in genetic and sporadic frontotemporal dementia. *Expert Review of Neurotherapeutics*, **2018**, 18, 469-475 | 4.3 | 4 |
| 23 | Effects of Multiple Genetic Loci on Age at Onset in Frontotemporal Dementia. *Journal of Alzheimerjs Disease*, **2017**, 56, 1271-1278 | 4.3 | 3 |
| 22 | MRI helps depict clinically undetectable risk factors in advanced stage retinoblastomas. *Neuroradiology Journal*, **2015**, 28, 53-61 | 2 | 3 |
| 21 | MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**, | 5.5 | 3 |
| 20 | Plasma Screening for Progranulin Mutations in Patients with Progressive Supranuclear Palsy and Corticobasal Syndromes. *Journal of Alzheimerjs Disease*, **2016**, 53, 445-9 | 4.3 | 3 |
| 19 | Brain temperature in multiple sclerosis. *Multiple Sclerosis Journal*, **2014**, 20, 894-6 | 5 | 2 |
| 18 | Transmembrane protein 106B gene (TMEM106B) variability and influence on progranulin plasma levels in patients with Alzheimer's disease. *Journal of Alzheimerjs Disease*, **2015**, 43, 757-61 | 4.3 | 2 |
| 17 | Partial recovery after severe immune reconstitution inflammatory syndrome in a multiple sclerosis patient with progressive multifocal leukoencephalopathy. *Immunotherapy*, **2014**, 6, 23-8 | 3.8 | 2 |
| 16 | FUS/TLS genetic variability in sporadic frontotemporal lobar degeneration. *Journal of Alzheimerjs Disease*, **2010**, 19, 1317-22 | 4.3 | 2 |
| 15 | Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum NfL and pNfH: A Longitudinal Multicentre Study. *Annals of Neurology*, **2021**, | 9.4 | 2 |
| 14 | A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status. *Journal of Visualized Experiments*, **2016**, | 1.6 | 2 |
| 13 | C9ORF72 hexanucleotide repeat expansion frequency in patients with Paget's disease of bone. *Neurobiology of Aging*, **2020**, 85, 154.e1-154.e3 | 5.6 | 2 |
| 12 | Disease-related cortical thinning in presymptomatic granulin mutation carriers. *NeuroImage: Clinical* , **2021**, 29, 102540 | 5.3 | 2 |
| 11 | Binge eating and fast cognitive worsening in an early-onset bvFTD patient carrying C9ORF72 expansion. *Neurocase*, **2015**, 21, 543-7 | 0.8 | 1 |

| | | | |
|---|---|---|---|
| 10 | Profiling of Specific Gene Expression Pathways in Peripheral Cells from Prodromal Alzheimer's Disease Patients. *Journal of Alzheimerjs Disease*, **2018**, 61, 1289-1294 | 4.3 | 1 |
| 9 | No association of IFI16 (interferon-inducible protein 16) variants with susceptibility to multiple sclerosis. *Journal of Neuroimmunology*, **2014**, 271, 49-52 | 3.5 | 1 |
| 8 | Frontotemporal Lobar Degeneration **2015**, 57-66 | | 1 |
| 7 | Progress in multiple sclerosis research in the last year. *Journal of Neurology*, **2012**, 259, 1497-501 | 5.5 | 1 |
| 6 | Alzheimer's disease: from pathogenesis to novel therapeutic approaches. *Therapy: Open Access in Clinical Medicine*, **2009**, 6, 259-277 | | 1 |
| 5 | Cell-dependent kinase inhibitor 2A and 2B genetic variability in patients with Alzheimer's disease. *Journal of Neurology*, **2011**, 258, 704-5 | 5.5 | 0 |
| 4 | Lack of Association between the GPR3 Gene and the Risk for Alzheimer's Disease. *International Journal of Alzheimerjs Disease*, **2011**, 2011, 576143 | 3.7 | |
| 3 | Disease-modifying drugs in multiple sclerosis: new oral options. *Clinical Practice (London, England)*, **2012**, 9, 315-327 | 3 | |
| 2 | Frontotemporal Lobar Degeneration: Genetics and Clinical Phenotypes **2014**, 93-109 | | |
| 1 | Estrogens need insulin-like growth factor I cooperation to exert their neuroprotective effects in post-menopausal women. *Journal of Endocrinological Investigation*, **2013**, 36, 97-103 | 5.2 | |